MENU
ATNM
Stock ticker: ASE
PRICE
CHANGE
CAPITALIZATION

ATNM stock forecast, quote, news & analysis

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells... Show more

Industry: #Biotechnology
ATNM
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for ATNM with price predictions
Jul 10, 2026

ATNM's Stochastic Oscillator dives into oversold zone

The Stochastic Oscillator for ATNM moved into oversold territory on July 10, 2026. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ATNM's RSI Oscillator exited the oversold zone, of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ATNM just turned positive on June 30, 2026. Looking at past instances where ATNM's MACD turned positive, the stock continued to rise in of 50 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ATNM advanced for three days, in of 231 cases, the price rose further within the following month. The odds of a continued upward trend are .

ATNM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on July 08, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ATNM as a result. In of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

ATNM moved below its 50-day moving average on June 03, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ATNM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for ATNM entered a downward trend on July 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.330) is normal, around the industry mean (22.885). P/E Ratio (0.000) is within average values for comparable stocks, (37.796). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.508). ATNM has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (312.500) is also within normal values, averaging (434.181).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ATNM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ATNM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Nektar Therapeutics (NASDAQ:NKTR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.17B. The market cap for tickers in the group ranges from 58 to 121.89B. VRTX holds the highest valuation in this group at 121.89B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -3%. For the same Industry, the average monthly price growth was 7%, and the average quarterly price growth was 1,806%. FBRX experienced the highest price growth at 116%, while ENLV experienced the biggest fall at -94%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 8%. For the same stocks of the Industry, the average monthly volume growth was -20% and the average quarterly volume growth was -36%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 80
Price Growth Rating: 52
SMR Rating: 94
Profit Risk Rating: 92
Seasonality Score: 1 (-100 ... +100)
View a ticker or compare two or three
ATNM
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a biopharmaceutical company developing targeted payload immunotherapeutic for the treatment of advanced cancers

Industry Biotechnology

Profile
Details
Industry
Biotechnology
Address
100 Park Avenue
Phone
+1 646 677-3870
Employees
25
Web
https://www.actiniumpharma.com
ATNM's Stochastic Oscillator dives into oversold zone